hVIVO plc Exercise of Share Options (5785O)
02 Octobre 2019 - 6:03PM
UK Regulatory
TIDMHVO
RNS Number : 5785O
hVIVO plc
02 October 2019
HVIVO plc
("hVIVO" or the "Company")
Exercise of Share Options
London, UK, 2 October 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, announces
that, following the exercise of employee share options by
ex-employees, application has been made to AIM for the admission of
89,482 new ordinary shares of 5 pence each (the "New Ordinary
Shares"). Admission to trading on AIM of the New Ordinary Shares
("Admission"), which will rank pari passu in all respects with the
Company's existing shares in issue, is expected to occur on 8
October 2019.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 83,209,902 and this figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
For further information please contact:
hVIVO plc
Anesh Patel (Interim Finance Director & Company Secretary) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 100
Notes to Editors:
hVIVO is an industry leading clinical development services
business supporting product development for customers developing
antivirals, vaccines and respiratory therapeutics. Leveraging human
disease models in human rhinovirus (HRV), RSV, Influenza (Flu)
Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO
platform illuminates the entire disease cycle in people from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted 56 clinical studies and inoculated over 2900
volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSQLLFBKBFBFBB
(END) Dow Jones Newswires
October 02, 2019 12:03 ET (16:03 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024